2 terminated, 1 active not recruiting. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Active not recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow BPX-501 T cells: new trials by email Literature Review of BPX-501 T cells trials Research Report on BPX-501 T cells
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS rivogenlecleucel, rimiducid, Cyclophosphamide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Terminated | Bellicum Pharmaceuticals | 1 | 2018-12-27 | 2023-09-29 |
| Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant BPX-501 T cells, Rimiducid - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Active not recruiting | Bellicum Pharmaceuticals | 120 | 2014-04-01 | 2022-07-12 |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant BPX-501 T cells, Rimiducid - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 187 | 2014-04-01 | 2023-09-29 |
Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Anemia, Aplastic (2) · Cytopenia (2) · Hematologic Neoplasms (2) · Leukemia (2) · Lymphoma, Non-Hodgkin (2) · Osteopetrosis (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Primary Immunodeficiency Diseases (2) · Anemia (1) · Anemia, Diamond-Blackfan (1) · Anemia, Sickle Cell (1) · Fanconi Anemia (1) · Hemoglobinopathies (1)
United States (2) · Italy (1) · United Kingdom (1)